The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia

Imatinib mesylate is a potent and high selective inhibitor of Bcr-Abl tyrosine kinase, which is established now as the standard of Philadelphia chromosome positive (Ph) chronic myeloid leukemia (CML) treatment. The treatment of patients with chronic phase of CML with imatinib has resulted in high rates of hematologic and cytogenetic responses. Nevertheless, primary and acquired resistance have been observed in few CML patients. The mechanisms of resistance to imatinib and its clinical significance were discussed in this review

Estimation of clinical efficiency of topical combination therapy patients with pyoderma complicated eczema

The results of direct open-label study of efficacy and portability of combination therapy with topical betamethasone dipropionate and mupirocin are presented. Material and methods. Twenty two patients with pyoderma complicated eczema were treated with ointment for external use (betamethasone dipropionate and mupirocin) 2 times a day for 14 days. Clinical efficacy was assessed by the reliability decrease of index EASI and dermatological symptoms scale index (DSSI). Results. Clinical convalescense was achieved in all patients by the 14th day of therapy. There was a statistically significant decrease in the indices EASI, DSSI. Portability were well. Conclusion. Our study results showed clinical efficacy and portability of topical combination therapy of betamethasone dipropionate and mupirocin in patients with pyoderma complicated eczema